CD274 and pancreatic ductal adenocarcinoma: Studies have demonstrated that the combination therapy of Gal-9 and PD-L1 can enhance the effectiveness of anti-PD-L1 antibody therapy in patients with pancreatic ductal adenocarcinoma (Li et al., 2023).